The feasibility of region-resolved proteomics in individual murine aortas is demonstrated and new molecular insights into the site-specific nature of atherosclerotic plaque development are provided.
Abstract
Background and aims Atherosclerotic plaques form preferentially at vascular sites exposed to disturbed blood flow, yet the protein changes underlying this site-specific plaque development remain unclear. Mouse models are widely used to study atherosclerosis but yield only limited amounts of tissue, previously restricting proteomic studies. However, recent advances in mass spectrometry now enable proteomic profiling of very small tissue samples. We aimed to utilise this to uncover site-specific protein changes in aortic regions prone or resistant to plaque formation. Methods Aortic arches from apolipoprotein E-deficient (ApoE−/−) mice fed a Western diet (WD) for 16 weeks were dissected into plaques from the major branches and inner curvature and visibly healthy regions. Proteins were extracted, enzymatically digested, and analysed by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Results More than 4000 proteins were identified per sample despite their small size (< 1 mg tissue). Principal component analysis showed clustering by both disease status and anatomical location within the aortic arch, indicating distinct proteomes. Proteins known to drive atherosclerosis – including vascular cell adhesion molecule 1 (Vcam1), apolipoprotein B (Apob), lipoprotein lipase (Lpl), and galectin 3 (Lgals3) – were most abundant in advanced plaques and decreased progressively across anatomical regions, reaching their lowest levels in ‘healthy’ regions furthest from the plaques. Enrichment analysis highlighted pathways related to the extracellular matrix, immune system, hemostasis, and lipoprotein transport as central to disease progression. Conclusions This study demonstrates the feasibility of region-resolved proteomics in individual murine aortas and provide new molecular insights into the site-specific nature of atherosclerotic plaque development.
Comparisons of LC-MS/MS analyses of plasma-derived EVs and plasma from subjects with impaired vascular status and healthy controls illustrate the potential of LC-MS/MS to examine the role of inflammation and arterial wall cells in shaping the proteome of EVs and plasma in health and disease.
Yibo Gao, L. Lorentzen, Emily M Martin et al.· Bioscience Reports· 0 citations
BACKGROUND AND AIMS
All apolipoprotein B-containing lipoproteins are established causal factors for coronary artery disease (CAD). This study aimed to identify robust proteomic signatures of low-density lipoprotein (LDL), triglyceride-rich lipoproteins (TRL), and lipoprotein(a) [Lp(a)] and to evaluate whether these sig...
J. Morze, E. Björnson, Michael Y. Mi et al.· European Heart Journal· 0 citations
Together, AtherOMICS enables multimodal characterization of human atherosclerosis aiming for the discovery of athero-specific drug targets, molecular signatures of atheroprogression, and noninvasive biomarkers of plaque vulnerability.
L. Živković, R. Batool, J. Louma et al.· Science Advances· 0 citations
Deep proteomic profiling of human carotid plaques identifies molecular signatures of symptomatic atherosclerosis that extend beyond conventional histopathology, which implicate neutrophil activation and inflammatory signaling pathways as key determinants of plaque vulnerability.
L. Zhang, L. Živković, A. Ray et al.· medRxiv· 0 citations
This proof-of-concept study suggests the potent low-hemorrhage antithrombotic effect of MK by targeting FXIa and unveiling a new therapeutic application of MK.
The results indicate that cardiopulmonary HIF2 signaling prevents excessive vascular proliferation during chronic hypoxia and define novel protective roles of HIF2 to warrant stable microvasculature and organ function.
L. Curtiss, Göran K. Hansson, P. Libby et al.· Arteriosclerosis, Thrombosis...· 54 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.